Table 2.
Kaplan–Meier estimated overall survival of HGSOC patients
| Variable | Cases
|
Overall survival (months)
|
5-year overall survival | P-value |
|---|---|---|---|---|
| (n=97) | Mean ± SD | |||
| Age (years) | 0.616 | |||
| ≤60.0 | 37 | 56.9±4.4 | 29.5% | |
| >60.0 | 60 | 54.4±3.5 | 34.8% | |
| Pathological grade | 0.251 | |||
| Grade 1–2 | 28 | 59.4±5.0 | 45.8% | |
| Grade 3 | 69 | 51.5±2.7 | 24.7% | |
| FIGO stage | 0.004* | |||
| Stage I–II | 6 | 71.2±11.9 | 60.0% | |
| Stage III | 72 | 55.6±2.9 | 32.5% | |
| Stage IV | 19 | 37.3±4.7 | 11.8% | |
| CA-125 (U/mL) | 0.114 | |||
| ≤35 | 12 | 66.0±6.1 | 47.6% | |
| >35 | 85 | 51.7±2.6 | 29.8% | |
| PTPL1 expression | 0.042* | |||
| Low | 36 | 48.3±4.1 | 25.8% | |
| High | 61 | 59.5±3.6 | 40.7% |
Note:
*
p<0.05.
Abbreviations: CA-125, cancer antigen 125; HGSOC, high-grade serous ovarian cancer; PTPL1, protein tyrosine phosphatase L1.